rais est reflect benefit lower tax rate
rais estim edward follow compani
commentari last week morgan healthcar confer
anticip impact us tax reform manag forecast
effect tax rate last month
decemb analyst meet reduct edward add
ep estim go last week assum rate
today weve lower assumpt reflect
benefit model assumpt manag invest
balanc wont easi
new estim
compar previous street consensu
obvious well ahead street
margin assumpt notabl conserv
increment sg spend vs top-
line estim larg in-lin street vs
updat edward await european approv
sapien ultra centera transcathet valv expect
year-end expect shortli ultra incorpor uniqu skirt design
valv pre-mount balloon well next gener
sheath deliveri system centera compani highli anticip entri
self-expand side tavr market month outcom data
present tct publish decemb us approv ultra expect
late trial centera start year
expect strong edward channel check us tavr
market encourag weve multipl report indic
uptick procedur volum us european devic market
suggest strong card broader medic devic space
forecast quarter call revenu report
organ ep assum us tavr growth
sequenti global thv revenu
report organ includ cardioband
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
edward ralli last week back tax commentari like
enjoy strength right quarter said continu
view ew stori investor look forward releas
edward medtron risk tavr trial march
compani transcathet mitral tricuspid repair program
begin ramp meaning contribut top-lin perform
first time therefor look like transit year albeit project
top-lin ep growth see upsid consensu forecast
beyond fourth quarter meaning top-lin beat may harder come
tavr market slow amidst absenc catalyst prior risk data
clear still bullish edward outlook think
investor want revisit share get closer tavr-
driven revenu beat less like meaning mitral tricuspid
catalyst see share take breather post print
beyond health tavr market view edward emerg
pipelin mitral tricuspid repair key multipl expans
decemb analyst meet edward forecast market mitral tricuspid
therapi grow forecast seem
reason think abbott mitraclip track
reach alon model edward
edward pipelin actual fairli robust five novel transcathet
repair product potenti launch europ next
month start cardioband mr direct annuloplasti approach
mitral valv repair acquir edward valtech transact cardioband
mr launch europ follow edward refin train
program build-out mitral clinic support team model
cardioband gener sale rise includ
late us approv cardioband mr us pivot trial activ
enrol expect complet enrol follow-up
expect cardioband tr receiv ce mark
follow pascal tmv repair system follow complet
follow-up clasp decemb close
harpoon medic acquisit edward also plan launch devic
europ us launch line european approv
immin expect edward begin train launch
product sale grow final
edward place forma tricuspid spacer program hold better enhanc
devic procedur resum implant later
mileston watch includ follow-up
cardioband tr earli feasibl trial like pcr may result
clasp pascal ce mark trial like tct septemb
edward test next-gener cardiaq valv deliveri system
year-end price target edward previous valu
share upwardli revis ep estim
invest thesi valuat risk
edward set stori revenu grow ep
investor like look forward releas
edward medtron risk tavr trial march
compani transcathet mitral tricuspid repair program begin ramp
meaning contribut top-lin perform first time therefor
transit year albeit project top-lin bottom-lin growth
come risk howev tavr market slow last sever
quarter like slow get risk trial
fulli expect posit therefor catalyst absent top-lin upsid
meaning pipelin catalyst next month think edward shape
stori investor want revisit later year remain
dec price target edward previous valu
share upwardli revis ep estim repres
signific premium current large-cap med-tech averag ntm ep
believ premium justifi given edward differenti outlook top
bottom line
risk rate price
upsid risk rate includ better-than-expect tavr growth competitor
pipelin product failur better-than-expect critic perform
favor chang tavr procedur reimburs particularli intern
downsid risk rate includ increas competit us
clinic trial result setback compani transcathet mitral program
edward lifesci summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
